Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Prosthetics
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:PODD
- CUSIP: 45784P10
- Web: www.insulet.com
- Market Cap: $2.97865 billion
- Outstanding Shares: 57,916,000
- 50 Day Moving Avg: $48.42
- 200 Day Moving Avg: $44.12
- 52 Week Range: $30.69 - $52.79
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -376.86
- P/E Growth: -4.29
- Annual Revenue: $387.49 million
- Price / Sales: 7.89
- Book Value: $1.10 per share
- Price / Book: 47.96
- EBIDTA: $11.22 million
- Net Margins: -6.81%
- Return on Equity: -48.46%
- Return on Assets: -6.57%
- Debt-to-Equity Ratio: 5.30%
- Current Ratio: 8.56%
- Quick Ratio: 7.69%
- Average Volume: 445,852 shs.
- Beta: 1.55
- Short Ratio: 9.89
Frequently Asked Questions for Insulet Corporation (NASDAQ:PODD)
What is Insulet Corporation's stock symbol?
Insulet Corporation trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet Corporation's earnings last quarter?
Insulet Corporation (NASDAQ:PODD) posted its earnings results on Monday, May, 8th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The company had revenue of $101.70 million for the quarter, compared to analysts' expectations of $97.73 million. Insulet Corporation had a negative net margin of 6.81% and a negative return on equity of 48.46%. The business's revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.19) earnings per share. View Insulet Corporation's Earnings History.
Where is Insulet Corporation's stock going? Where will Insulet Corporation's stock price be in 2017?
14 equities research analysts have issued twelve-month price objectives for Insulet Corporation's stock. Their predictions range from $38.00 to $52.00. On average, they expect Insulet Corporation's share price to reach $47.42 in the next year. View Analyst Ratings for Insulet Corporation.
What are analysts saying about Insulet Corporation stock?
Here are some recent quotes from research analysts about Insulet Corporation stock:
- 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (7/20/2017)
- 2. Northland Securities analysts commented, "Regulatory Filings Falling into Place. With the FDA BLA formal submission expected next week, Spark has shifted its focus towards its MAA filing for Europe and pre-commercialization activities." (5/9/2017)
- 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
- 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)
Who are some of Insulet Corporation's key competitors?
Some companies that are related to Insulet Corporation include United Therapeutics Corporation (UTHR), Mednax (MD), Hill-Rom Holdings (HRC), ICON PLC (ICLR), Masimo Corporation (MASI), Charles River Laboratories International (CRL), Mallinckrodt PLC (MNK), PRA Health Sciences (PRAH), Taro Pharmaceutical Industries (TARO), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Acadia Healthcare Company (ACHC), Hikma Pharmaceuticals Plc (HKMPF), Alere (ALR), Bio-Techne Corp (TECH), Medidata Solutions (MDSO), bluebird bio (BLUE) and Clovis Oncology (CLVS).
Who are Insulet Corporation's key executives?
Insulet Corporation's management team includes the folowing people:
- Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer
- Shacey Petrovic, President, Chief Operating Officer
- Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer
- Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development
- David Colleran J.D., Senior Vice President, General Counsel, Secretary
- Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering
- Charles Alpuche, Senior Vice President - Global Manufacturing and Operations
- Michael Spears, Senior Vice President - Quality and Regulatory Affairs
- Bret Christensen, Chief Commercial Officer
- Jessica Hopfield Ph.D., Lead Independent Director
Who owns Insulet Corporation stock?
Insulet Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.66%), KAMES CAPITAL plc (0.09%), Moreno Evelyn V (0.06%), Tributary Capital Management LLC (0.05%), Russell Investments Group Ltd. (0.05%) and Fisher Asset Management LLC (0.03%). Company insiders that own Insulet Corporation stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet Corporation.
Who sold Insulet Corporation stock? Who is selling Insulet Corporation stock?
Insulet Corporation's stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, OLD National Bancorp IN and Bank of Montreal Can. Company insiders that have sold Insulet Corporation stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet Corporation.
Who bought Insulet Corporation stock? Who is buying Insulet Corporation stock?
Insulet Corporation's stock was acquired by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Rockefeller Financial Services Inc., Russell Investments Group Ltd. and Diversified Trust Co. Company insiders that have bought Insulet Corporation stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet Corporation.
How do I buy Insulet Corporation stock?
Shares of Insulet Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet Corporation's stock price today?
MarketBeat Community Rating for Insulet Corporation (NASDAQ PODD)MarketBeat's community ratings are surveys of what our community members think about Insulet Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Insulet Corporation stock can currently be purchased for approximately $52.76.
Consensus Ratings for Insulet Corporation (NASDAQ:PODD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||6 Hold Ratings, 8 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.57)|
|Consensus Price Target: ||$47.42 (10.13% downside)|
Analysts' Ratings History for Insulet Corporation (NASDAQ:PODD)
(Data available from 7/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/22/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Hold||High|
|7/17/2017||BTIG Research||Downgrade||Buy -> Neutral||Medium|
|7/14/2017||Cowen and Company||Reiterated Rating||Buy||$52.00||Medium|
|7/14/2017||Jefferies Group LLC||Reiterated Rating||Buy||$48.00||Low|
|7/11/2017||Canaccord Genuity||Reiterated Rating||Hold||$42.00 -> $50.00||Low|
|5/25/2017||William Blair||Reiterated Rating||Outperform -> Outperform||Low|
|5/22/2017||Piper Jaffray Companies||Reiterated Rating||Overweight -> Overweight||$47.00||Low|
|5/14/2017||B. Riley||Reiterated Rating||Neutral||$44.00||Low|
|5/9/2017||Northland Securities||Reiterated Rating||Buy||$50.00||High|
|2/28/2017||Wedbush||Boost Price Target||Outperform -> Outperform||$48.00 -> $50.00||N/A|
|2/27/2017||Feltl & Co.||Downgrade||Buy -> Hold||N/A|
|1/6/2017||Robert W. Baird||Upgrade||Neutral -> Outperform||$39.00 -> $47.00||N/A|
|11/17/2016||J P Morgan Chase & Co||Reiterated Rating||Hold||$38.00||N/A|
|11/7/2016||Leerink Swann||Reiterated Rating||Outperform||$55.00 -> $50.00||N/A|
|5/16/2016||Sterne Agee CRT||Reiterated Rating||Neutral||N/A|
|2/26/2016||Benchmark Co.||Upgrade||Hold -> Buy||$30.00 -> $40.00||N/A|
|11/2/2015||Morgan Stanley||Initiated Coverage||Equal -> Equal Weight||$32.00||N/A|
Earnings History for Insulet Corporation (NASDAQ:PODD)Earnings History by Quarter for Insulet Corporation (NASDAQ PODD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/8/2017||Q1 2017||($0.16)||($0.17)||$97.73 million||$101.70 million||View||Listen|
|2/27/2017||Q416||($0.05)||($0.16)||$100.61 million||$103.58 million||View||Listen|
|11/3/2016||Q316||($0.09)||($0.05)||$89.75 million||$94.90 million||View||N/A|
|8/3/2016||Q216||($0.17)||($0.08)||$81.10 million||$87.30 million||View||N/A|
|4/28/2016||Q116||($0.19)||($0.19)||$79.06 million||$81.21 million||View||Listen|
|2/25/2016||Q415||($0.26)||($0.48)||$91.89 million||$100.10 million||View||Listen|
|11/5/2015||Q315||($0.26)||($0.33)||$83.56 million||$87.30 million||View||Listen|
|8/12/2015||Q215||($0.13)||($0.27)||$70.32 million||$75.60 million||View||Listen|
|4/30/2015||Q115||($0.10)||($0.21)||$68.20 million||$61.20 million||View||N/A|
|2/26/2015||Q414||($0.04)||($0.10)||$73.52 million||$72.60 million||View||N/A|
|8/7/2014||Q214||($0.08)||($0.06)||$72.94 million||$72.00 million||View||N/A|
|5/7/2014||Q114||($0.06)||($0.11)||$68.47 million||$69.20 million||View||N/A|
|2/27/2014||Q413||($0.09)||($0.04)||$67.94 million||$68.53 million||View||N/A|
|11/7/2013||Q313||($0.16)||($0.39)||$62.01 million||$61.10 million||View||N/A|
|8/7/2013||Q2 2013||($0.19)||($0.20)||$60.47 million||$60.09 million||View||N/A|
|5/6/2013||Q1 2013||($0.21)||($0.20)||$57.26 million||$57.40 million||View||N/A|
|2/27/2013||Q4 2012||($0.21)||($0.21)||$59.12 million||$57.80 million||View||N/A|
|11/8/2012||Q312||($0.22)||($0.26)||$54.93 million||$54.80 million||View||N/A|
Earnings Estimates for Insulet Corporation (NASDAQ:PODD)
2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.08)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Insulet Corporation (NASDAQ:PODD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Insulet Corporation (NASDAQ:PODD)
Insider Ownership Percentage: 2.60%Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/16/2017||Michael P. Spears||SVP||Buy||2,500||$40.59||$101,475.00|| |
|5/11/2017||Bradley A. Thomas||EVP||Buy||3,000||$38.69||$116,070.00|| |
|5/11/2017||Jessica Hopfield||Director||Buy||2,580||$38.68||$99,794.40|| |
|5/1/2017||David A. Lemoine||Director||Sell||1,524||$43.40||$66,141.60|| |
|3/13/2017||Regina O. Sommer||Director||Sell||40,000||$45.00||$1,800,000.00|| |
|3/6/2017||David A. Lemoine||Director||Sell||1,282||$45.15||$57,882.30|| |
|3/2/2017||Joseph S. Zakrzewski||Director||Sell||40,000||$46.86||$1,874,400.00|| |
|12/9/2016||Charles Alpuche||SVP||Buy||6,600||$37.70||$248,820.00|| |
|12/2/2016||Patrick J. Sullivan||CEO||Buy||40,000||$33.89||$1,355,600.00|| |
|12/1/2016||Bradley A. Thomas||EVP||Buy||3,100||$32.45||$100,595.00|| |
|5/25/2016||Regina O Sommer||Director||Sell||8,019||$30.42||$243,937.98|| |
|5/18/2016||Patrick J Sullivan||CEO||Buy||45,000||$27.00||$1,215,000.00|| |
|5/13/2016||Bradley A Thomas||EVP||Buy||2,975||$26.63||$79,224.25|| |
|5/5/2016||Bradley A Thomas||EVP||Buy||1,656||$30.13||$49,895.28|| |
|3/10/2016||Daniel J Levangie||Insider||Sell||12,299||$30.89||$379,916.11|| |
|3/7/2016||Daniel J Levangie||Insider||Sell||7,663||$31.15||$238,702.45|| |
|3/2/2016||Jessica Hopfield||Director||Buy||3,230||$30.91||$99,839.30|| |
|6/5/2015||Patrick J Sullivan||CEO||Buy||10,000||$29.39||$293,900.00|| |
|5/28/2015||Patrick J Sullivan||CEO||Buy||20,000||$27.91||$558,200.00|| |
|5/15/2015||Timothy J Scannell||Director||Buy||3,500||$27.05||$94,675.00|| |
|5/5/2015||Bradley A Thomas||EVP||Buy||1,000||$27.26||$27,260.00|| |
|5/5/2015||Patrick Ryan||COO||Buy||3,669||$26.99||$99,026.31|| |
|4/2/2015||R Anthony Diehl||General Counsel||Sell||3,372||$30.96||$104,397.12|| |
|3/9/2015||Patrick J Sullivan||CEO||Buy||10,000||$31.93||$319,300.00|| |
|3/2/2015||Charles T Liamos||Director||Sell||4,000||$32.00||$128,000.00|| |
|2/12/2015||Charles T Liamos||Director||Sell||4,000||$32.00||$128,000.00|| |
|1/2/2015||Charles T Liamos||Director||Sell||4,000||$46.08||$184,320.00|| |
|11/3/2014||Charles T Liamos||Director||Sell||4,000||$42.95||$171,800.00|| |
|10/1/2014||Charles T Liamos||Director||Sell||4,000||$36.58||$146,320.00|| |
|10/1/2014||R Anthony Diehl||General Counsel||Sell||1,250||$36.59||$45,737.50|| |
|9/10/2014||Charles T Liamos||Director||Sell||4,000||$35.17||$140,680.00|| |
|9/2/2014||Duane Desisto||CEO||Sell||20,000||$36.30||$726,000.00|| |
|8/1/2014||Duane Desisto||CEO||Sell||20,000||$34.23||$684,600.00|| |
|7/1/2014||Duane Desisto||CEO||Sell||20,000||$40.52||$810,400.00|| |
|7/1/2014||R Anthony Diehl||General Counsel||Sell||1,250||$39.65||$49,562.50|| |
|6/11/2014||R Anthony Diehl||General Counsel||Sell||17,871||$37.09||$662,835.39|| |
|6/9/2014||Peter Devlin||Insider||Sell||12,314||$37.10||$456,849.40|| |
|4/8/2014||Peter Devlin||Insider||Sell||30,000||$41.25||$1,237,500.00|| |
|4/3/2014||R Anthony Diehl||General Counsel||Sell||4,617||$48.67||$224,709.39|| |
|3/6/2014||R Anthony Diehl||General Counsel||Sell||12,458||$49.28||$613,930.24|| |
|3/6/2014||Tracey Haas Wielinski||VP||Sell||8,275||$49.21||$407,212.75|| |
|2/3/2014||Charles Liamos||Director||Sell||11,037||$42.93||$473,818.41|| |
|2/3/2014||Duane Desisto||CEO||Sell||20,000||$42.95||$859,000.00|| |
|2/3/2014||Peter Devlin||Insider||Sell||30,000||$42.82||$1,284,600.00|| |
|1/3/2014||Charles Liamos||COO||Sell||86,000||$36.02||$3,097,720.00|| |
|1/2/2014||Duane Desisto||CEO||Sell||20,000||$36.07||$721,400.00|| |
|12/3/2013||Charles Liamos||COO||Sell||63,808||$36.26||$2,313,678.08|| |
|11/18/2013||Charles Liamos||COO||Sell||80,000||$35.60||$2,848,000.00|| |
|9/3/2013||Duane Desisto||CEO||Sell||20,000||$33.38||$667,600.00|| |
|8/29/2013||Sally Crawford||Director||Sell||9,000||$33.42||$300,780.00|| |
|8/15/2013||Regina Sommer||Director||Sell||5,000||$33.32||$166,600.00|| |
|8/1/2013||Duane Desisto||CEO||Sell||20,000||$31.85||$637,000.00|| |
|7/1/2013||Duane Desisto||CEO||Sell||20,000||$31.51||$630,200.00|| |
|7/1/2013||Peter Devlin||Insider||Sell||30,000||$31.48||$944,400.00|| |
|6/14/2013||Sally Crawford||Director||Sell||31,000||$30.47||$944,570.00|| |
|6/10/2013||R Anthony Diehl||General Counsel||Sell||38,455||$30.50||$1,172,877.50|| |
|6/3/2013||Duane Desisto||CEO||Sell||20,000||$29.76||$595,200.00|| |
|12/3/2012||Brian K Roberts||CFO||Sell||10,000||$21.92||$219,200.00|| |
|11/1/2012||Brian K Roberts||CFO||Sell||10,000||$21.49||$214,900.00|| |
|9/4/2012||Brian K Roberts||CFO||Sell||10,000||$20.78||$207,800.00|| |
|9/4/2012||Duane Desisto||CEO||Sell||20,000||$20.97||$419,400.00|| |
|9/4/2012||Ruthann Depietro||VP||Sell||1,000||$20.90||$20,900.00|| |
Headline Trends for Insulet Corporation (NASDAQ:PODD)
Latest Headlines for Insulet Corporation (NASDAQ:PODD)
Insulet Corporation (PODD) Chart for Tuesday, July, 25, 2017